Abstract
BRCA1 methylation may confer homologous recombination deficiency (HRD) in ovarian carcinomas and loss of methylation can be a mechanism of therapeutic resistance. We sought to develop and validate a clinical grade, quantitative assay for BRCA1 promoter methylation and characterize the impact of BRCA1 methylation in ovarian carcinoma.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
